Stay updated on Pembrolizumab for Metastatic TNBC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for Metastatic TNBC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for Metastatic TNBC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T20:22:50.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details of a Phase II Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC). This change may be significant for individuals monitoring medical and healthcare-related publications and documentation.
    Difference
    0.1%
    Check dated 2024-06-06T14:17:30.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying that neoadjuvant and/or adjuvant chemotherapy regimens do not count as a prior line of therapy. The new criteria outline specific health conditions and prior treatments required for inclusion in the study.
    Difference
    36%
    Check dated 2024-05-22T20:32:22.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:48:25.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for Metastatic TNBC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Metastatic TNBC Clinical Trial page.